HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Authorities Clamp Down On Unsafe Erectile Dysfunction Supplements In Q2

Executive Summary

Dietary supplements containing unsafe or unauthorized substances, including a number marketed to enhance sexual performance, were reported to the European Commission by national regulators on more than 50 occasions in the second quarter of 2023.

You may also be interested in...



‘Lack Of Understanding’ Here, Spiked Product There Add Up To US Supplement Industry Image Problem

Research suggesting FDA more stringently regulate claims for fish oil supplements impresses industry as another sign the agency’s regulation and the requirements fulfilled by compliant businesses aren’t appreciated or understood. FDA announcement of ED drugs in products labeled as supplements shows agency must be aware students are starting or returning to classes.

Nestlé Partner Valbiotis Hails Trial Results For Prediabetes Supplement

Valbiotis and Nestlé Health Science plan to launch in 2024 a dietary supplement targeted at sufferers of prediabetes and type-2 diabetes following positive results from a recent study which showed the product's efficacy on key markers of glucose metabolism.

Pierre Fabre Takes Stake In French Women's Health Start-Up

France's Pierre Fabre is enhancing its presence in the women's health market by taking a stake in dietary supplements and cosmetics firm MiYé.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153952

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel